
Amazon Stock To $100?
Over the past four years, Amazon has increased its revenue by $200 billion and $37 billion in net profit, with profits rising by 112% thanks to improving margins. However, during the same timeframe, its stock has only seen a 33% increase, and its price-to-earnings (P/E) ratio has dropped by 34%.
In 2021, Amazon's valuation multiple stood at 51 times earnings, signaling high expectations for future growth. Now, with a reduced multiple of 34x trailing earnings, investors are questioning whether this valuation remains justified, particularly as growth expectations are being moderated.
Now, we also have a contrasting scenario on Amazon Stock: Path To 2x Growth. Indeed, we believe that this wide range of upside and downside possibilities underscores a fundamental reality: AMZN is a volatile stock.
That being said, if you are looking for upside with less volatility than individual stocks, the Trefis High Quality portfolio offers an alternative — it has outperformed the S&P 500 and generated returns exceeding 91% since its launch. Additionally, see – The Trade Desk: Buy TTD Stock Now At $60?
Core Challenges and Investor Concerns
A variety of factors contribute to investor anxiety, presenting potential obstacles for Amazon's stock.
AWS has traditionally been Amazon's main source of profit, with estimated adjusted EBITDA margins around 45%, compared to 15% for its North American operations and 11% for its international businesses. Any slowdown in this segment greatly influences the company's overall profitability and investor confidence.
While Amazon's Q2 AWS growth of 18% topped analyst projections, it lagged behind the growth rates of its primary rivals, Microsoft Azure (39%) and Google Cloud (32%). This gap is a significant reason for the stock's recent slump, as investors fear that AWS is losing its competitive edge in the key cloud market. Even a notable partnership with OpenAI has not fully alleviated these worries.
The surge in AI has heightened demand for cloud services, yet some view Amazon as falling behind its competitors. Rivals like Microsoft and Google offer highly integrated AI solutions (like GPT and Gemini, respectively), which are often simpler for customers to adopt. Conversely, AWS's approach frequently necessitates greater technical expertise from developers to combine various services.
Wider economic factors present additional threats for Amazon:
Historical Performance During Downturns
Amazon's stock has shown volatility during previous market downturns, sometimes performing worse than the S&P 500 index.
The substantial 55% drawdown in 2022 indicates that a significant drop from current levels is not unusual. This history of volatility, combined with a high stock price, leads to cautious investor sentiment. See – Buy or Sell AMZN Stock – for more details.
The Verdict
To summarize, it also does not aid that AMZN stock remains expensive; it trades at nearly 34x trailing earnings. Certainly, the company's revenue has increased significantly over recent years, growing at an average rate of about 11% over the last three years (compared to 5% for the S&P 500). However, this growth might diminish rapidly if the economy worsens and if the company fails to adequately seize its share of the AI cloud market. At existing multiples, even slight disappointments could prompt a disproportionate correction in the stock, as demonstrated by its performance following its positive Q2 results.
The high valuation of AMZN stock could restrict its upside potential in the near to medium term. Alternatively, the Trefis Reinforced Value (RV) Portfolio has outperformed its all-cap stocks benchmark (a combination of the S&P 500, S&P mid-cap, and Russell 2000 benchmark indices), delivering strong returns for investors. Why is this the case? The quarterly rebalanced combination of large-, mid-, and small-cap RV Portfolio stocks has provided a responsive means to capitalize on favorable market conditions while limiting losses during downturns, as detailed in RV Portfolio performance metrics.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


WIRED
a minute ago
- WIRED
Lovense's Gemini Sex Toy Offers a Fresh Sensation in the Bedroom—No AI Needed
I've never had particularly sensitive nipples—except for the first time I went to a clothing-optional beach and failed to use enough sunblock—so I was excited to give the Lovense Gemini a try. No, it has nothing to do with Google's AI chatbot. These are vibrating nipple clamps from Lovense, and I've had great experience with many of the company's sex toys. Many of my partners have had sensitive nipples, so I was curious if I could join the ranks with the Gemini. Usually sold for less than $80, they're an inexpensive way to spice up the bedroom. Great for Enthusiasts and Beginners Courtesy of Amazon After I fully charged the Gemini, which takes about an hour or so, I used it on myself. What I love is that I can clip the base of the clamps to my bra (there's also a cord you can put around your neck if you don't wear a bra), making them 100 percent hands-free. The Gemini is app-controlled (Android, iOS), so I can lie back and play with the slew of intensities and patterns—surprisingly fun even though I was solo. When I added a bullet vibrator to the mix, the vibrations all over made everything even more exciting in a low-key, kinky sort of way. I also appreciate that the clamps are adjustable, so if you love a tight squeeze, a barely there hold, or somewhere in between, you have options. Unlike some of the more intimate toys I've reviewed, like the Luxus Couples Vibrator or the Lelo Ora 3, I was able to get input from a handful of people with the Gemini. Especially people I know who really (like, really ) love nipple play. As much as I enjoyed the vibrations and found the sensation interesting, the Gemini made me realize that, ultimately, I prefer that my nipples get attention from a partner's tongue or with a slight graze of their teeth. Of the three nipple-play aficionados I used the Gemini with—one straight and two gay men—all of them became immediate fans of the toy. They liked the hands-free design and the simplicity of the Lovense Remote app. To paint a picture of this experiment, I had the app in hand, and three men sat on the couch across from me, waiting for their turn to try the Gemini. (It's the closest I'll probably ever get to an orgy.) Each man had a different preference in intensity and patterns, as well as the tightness of the clamps, so I was able to see just how much the Gemini can be the perfect fit for anyone who's into nipple play. Easy to Use The Gemini is well-built, too. Not only is it waterproof—for all those times you're craving a proper buzz on your nips while in the shower—but you also get a whopping two hours of run time when it's fully charged. The device is discreet, in case you're into public play where one partner enjoys the vibrations, while the other controls what they want you to feel.

Associated Press
17 minutes ago
- Associated Press
RCKT DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - August 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025, both dates inclusive (the 'Class Period'), of the important August 11, 2025 lead plaintiff deadline. SO WHAT: If you purchased Rocket Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Rocket Pharmaceuticals class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) RP-A501 was less effective than defendants had led investors to believe; (2) to increase its effectiveness, Rocket Pharmaceuticals amended RP-A501's clinical trial protocol by introducing a novel immunomodulatory agent; (3) the foregoing increased the risk that patients would suffer from a Serious Adverse Event ('SAE'); (4) accordingly, RP-A501's safety, as well as its clinical, regulatory, and commercial prospects, were overstated; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Rocket Pharmaceuticals class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit

Associated Press
17 minutes ago
- Associated Press
Now Live in the U.S.: Worldwide Club Offers for Travel Enthusiasts
NEW YORK, Aug. 10, 2025 /PRNewswire/ -- Travelzoo® (NASDAQ: TZOO), the club for travel enthusiasts, announces the release of Club Offers for Club Members in the U.S. Rigorously vetted and negotiated for us travel enthusiasts: Some offers have limited inventory and are subject to availability. Are you a travel enthusiast? Join the club today: About Travelzoo We, Travelzoo®, are the club for travel enthusiasts. We reach 30 million travelers. Club Members receive Club Offers personally reviewed by our deal experts around the globe. We have our finger on the pulse of outstanding travel, entertainment, and lifestyle experiences. We work in partnership with thousands of top travel suppliers—our long-standing relationships give us access to irresistible deals. Travelzoo is a registered trademark of Travelzoo. All other names are trademarks and/or registered trademarks of their respective owners. Media Contact: Paige Cram – Los Angeles +1 609 668 0645 [email protected] View original content to download multimedia: SOURCE Travelzoo